Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06632977 · ClinicalTrials.gov registry record · Phase 2

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

A Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Castration-Resistant Prostate Carcinoma, sponsored by Alliance for Clinical Trials in Oncology.

Recruiting
Registry status
Phase 2
Development phase
474
Enrollment target
20
Study locations

NCT06632977: Recruiting Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Castration-Resistant Prostate Carcinoma, sponsored by Alliance for Clinical Trials in Oncology.

NCT06632977 is a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Castration-Resistant Prostate Carcinoma that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 474 participants, above the 167-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (184% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06632977, a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Castration-Resistant Prostate Carcinoma, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.

RECRUITING
Registry status
Phase 2
Development phase
474 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of tumor cells. Abiraterone acetate blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of tumor cells that need androgens to grow. It is a type of anti-androgen. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Lutetium Lu 177 vipivotide tetraxetan is in a class of medications called radiopharmaceuticals. It works by targeting and delivering radiation directly to tumor cells which damages and kills these cells. Assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing

Primary Outcome

Objective response is defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Prostate Cancer Working Group 3 (PCWG3) for patients with measurable disease.

Conditions Studied

Stage IVB Prostate Cancer AJCC v8 Castration-Resistant Prostate Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Genetic testing
  • DRUG Valemetostat Tosylate
  • PROCEDURE Bone scan

Study Locations (20)

California

  • UC San Diego Health System - Encinitas - Encinitas
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
  • UC San Diego Moores Cancer Center - La Jolla
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
  • University of California Davis Comprehensive Cancer Center - Sacramento
  • UC San Diego Medical Center - Hillcrest - San Diego

Colorado

  • UCHealth Memorial Hospital Central - Colorado Springs
  • Memorial Hospital North - Colorado Springs
  • Poudre Valley Hospital - Fort Collins
  • Cancer Care and Hematology-Fort Collins - Fort Collins
  • UCHealth Greeley Hospital - Greeley
  • Medical Center of the Rockies - Loveland

Delaware

  • Beebe South Coastal Health Campus - Millville
  • Helen F Graham Cancer Center - Newark
  • Medical Oncology Hematology Consultants PA - Newark
  • Beebe Health Campus - Rehoboth Beach

Arizona

  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Florida

  • Jupiter Medical Center - Jupiter

Hawaii

  • Tripler Army Medical Center - Honolulu

Trial Details

FieldValue
Enrollment Target 474 participants
Start Date 2025-02-06
Est. Completion 2034-10-11
Phase Phase 2
Alliance for Clinical Trials in Oncology

446 total trials

What NCT06632977 shows while recruiting

NCT06632977 is an interventional study that assigns participants to a tested intervention. The registered 474 participants enrollment target is mid-sized for trials with a published cap, above the 167-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (184% higher).

The record links to 2 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT06632977 names 20 study sites across 6 states, led by California, Colorado, Delaware.

Frequently Asked Questions

What is clinical trial NCT06632977 about?

NCT06632977 is a clinical study titled "Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial". This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) ab...

What is the current status of trial NCT06632977?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 474 participants. The study started on 2025-02-06. Estimated completion is 2034-10-11.

What conditions does trial NCT06632977 study?

This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Castration-Resistant Prostate Carcinoma.

What interventions are being tested in trial NCT06632977?

The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Genetic testing (OTHER), Valemetostat Tosylate (DRUG), Bone scan (PROCEDURE).

Who is sponsoring clinical trial NCT06632977?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06632977 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IVB Prostate Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06632977's enrollment target sits among peer trials

474 6th of 45 higher than 40 of 45 other Stage IVB Prostate Cancer AJCC v8 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IVB Prostate Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05624996 · 474 participants · Phase 3

    Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • NCT06051695 · 474 participants · Phase 1

    A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • NCT01788839 · 475 participants

    Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

  • NCT05451303 · 475 participants

    Detection of Oral and Throat Cancers Using OralViome Cancer Testing System

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06632977

Source: ClinicalTrials.gov NCT06632977, the US trial registry maintained by the National Library of Medicine. NCT06632977 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.